Congrats mate, if you grow a second head you must post pix
Extremely good news, and, yet, difficult not to be saddened by the knowledge that the UK could've stayed out of this particular circle of hell by making better decisions in Autumn and early Winter. Lockdowns have worked for the UK—when they've been allowed to work. Hopefully, enough people will have been vaccinated to mitigate a future surge when restrictions are lifted.
It can be difficult to stick to what we know and what is proven in an incredibly urgent emergency such as the pandemic.
Somewhere back between p54 and p58 I explained that, because this is uncharted territory, and because these decisions about epidemic control strategies are so momentous, I believe they should be supported by certain kinds of data and analyses that can help us get a better idea of how risky our chosen course really is compared to the alternatives, under a wide range of plausible circumstances and assumptions. If you see that a particular strategy should be expected to result in a lower overall attack rate and death toll than other strategies, across a range of assumptions about key parameters (eg. vaccine efficacy in specific groups over time, risk of exposure and death, etc), that would be reassuring—and, if your circumstances were to go beyond that safe range, you would be able to respond quickly. It would probably improve the quality of the decision-making process, make it easier to evaluate performance (and hold people accountable ofc), facilitate course-corrections if necessary, help other countries—and, of course, increase our knowledge.
The AZN data is honestly not of very high quality if you're trying to answer these questions, but that vaccine is nevertheless somewhat easier to justify stretching in this manner in order to facilitate a breadth-first strategy (if you take off the immunology hat for a moment). I think it's interesting and useful to subject the careless reasoning about immunological concerns to scrutiny, but, pragmatically, we can focus on the epidemiological aspects of these questions. My gut feeling is that the primary benefit of a breadth-first strategy will be to mitigate the fallout from the govt's monumental fuckups in Autumn and early Winter, and to mitigate the potential negative impact of a premature easing of lockdown restrictions—but I think the overall attack rate may indeed be a little lower as well. I hope that the breadth-first strategy will also hasten the fall in case numbers to the point where the risk of exposure will be very low for any frail elderly institutionalized people that may have lost the protection conferred by the first dose of whatever vaccine they received.
Sure, or many people in priority group 4 would nevertheless have gotten their shots in a reasonable time-frame by being placed in a higher priority group.





Reply With Quote